Published in J Clin Neurosci on March 20, 2006
The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat (2013) 0.82
Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol (2009) 0.78
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol (2011) 6.77
SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature (2007) 4.33
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab (2003) 3.87
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67
Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain (2013) 3.22
Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol (2012) 3.12
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain (2008) 2.91
Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain (2002) 2.77
Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol (2010) 2.54
Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle (2007) 2.48
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry (2013) 2.33
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem (2008) 2.28
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med (2007) 2.28
Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol (2009) 2.25
Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain (2006) 2.25
Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med (2010) 2.24
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry (2012) 2.15
Impact of obesity on the predictive accuracy of prostate-specific antigen density and prostate-specific antigen in native Korean men undergoing prostate biopsy. Int J Urol (2014) 2.07
N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol (2009) 2.03
Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol (2003) 2.02
BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem (2003) 2.01
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid (2010) 2.01
Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol (2010) 1.99
Global proteomic profiling of native outer membrane vesicles derived from Escherichia coli. Proteomics (2007) 1.95
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet (2013) 1.91
Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain (2011) 1.89
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol (2004) 1.89
Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science (2006) 1.88
Head rotation, flexion, and extension alter endotracheal tube position in adults and children. Can J Anaesth (2009) 1.84
Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol (2003) 1.69
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol (2012) 1.67
The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2. J Biol Chem (2002) 1.66
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain (2012) 1.65
Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem Biophys Res Commun (2006) 1.63
Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J (2008) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology (2004) 1.56
N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord (2013) 1.55
Predicting the histology of small renal masses using preoperative dynamic contrast-enhanced magnetic resonance imaging. Urology (2012) 1.54
Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol (2012) 1.54
Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies. Clin Neurophysiol (2006) 1.54
Identification of synaptotagmin effectors via acute inhibition of secretion from cracked PC12 cells. J Cell Biol (2003) 1.51
Molecular classification of adult renal epithelial neoplasms using microRNA expression and virtual karyotyping. Diagn Mol Pathol (2011) 1.48
Pilomotor seizures and status in non-paraneoplastic limbic encephalitis. Epileptic Disord (2005) 1.47
An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature (2007) 1.46
[Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin]. Korean J Gastroenterol (2009) 1.45
Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry (2012) 1.45
Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci (2010) 1.45
A candidate gene for autoimmune myasthenia gravis. Neurology (2012) 1.44
The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr (2012) 1.43
Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol (2013) 1.40
Efficacy and safety of thrombolysis in patients aged 80 years or above with major acute ischemic stroke. Neurol India (2012) 1.39
Antibodies to voltage-gated potassium and calcium channels in epilepsy. Epilepsy Res (2006) 1.39
Antiglycine-receptor encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (2010) 1.38
Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann Neurol (2006) 1.37
The Cyt P450 enzyme CYP716A47 catalyzes the formation of protopanaxadiol from dammarenediol-II during ginsenoside biosynthesis in Panax ginseng. Plant Cell Physiol (2011) 1.37
Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res (2006) 1.37
Epigenetic inheritance in rice plants. Ann Bot (2007) 1.35
Anti-NMDA-receptor encephalitis: a cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol (2008) 1.32
Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci (2003) 1.32
Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev Med Child Neurol (2011) 1.32
Diagnostic value of ultrasonography to distinguish between benign and malignant lesions in the management of thyroid nodules. Thyroid (2007) 1.30
Prevalence and clinical characteristics of the metabolic syndrome in middle-aged Korean adults. Korean J Intern Med (2005) 1.25
Ion channels in genetic and acquired forms of epilepsy. J Physiol (2012) 1.24
Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia (2013) 1.22
Association of oxidative stress with postmenopausal osteoporosis and the effects of hydrogen peroxide on osteoclast formation in human bone marrow cell cultures. Calcif Tissue Int (2010) 1.22
Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol (2011) 1.21
NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease. J Neurol (2012) 1.21
Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies. Dev Med Child Neurol (2011) 1.20
Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol (2005) 1.20
Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. Cell Mol Life Sci (2011) 1.20
Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology (2014) 1.19
Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol (2005) 1.19
Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem (2010) 1.18
MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain (2006) 1.18
FGF2-activated ERK mitogen-activated protein kinase enhances Runx2 acetylation and stabilization. J Biol Chem (2009) 1.16
Four novel RUNX2 mutations including a splice donor site result in the cleidocranial dysplasia phenotype. J Cell Physiol (2006) 1.16
Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry (2012) 1.16
Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve (2004) 1.15
Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol (2005) 1.14
Cytochrome P450 CYP716A53v2 catalyzes the formation of protopanaxatriol from protopanaxadiol during ginsenoside biosynthesis in Panax ginseng. Plant Cell Physiol (2012) 1.13
Autoimmune epilepsy in children: case series and proposed guidelines for identification. Epilepsia (2013) 1.13
Clinical Diversity of SCN4A-Mutation-Associated Skeletal Muscle Sodium Channelopathy. J Clin Neurol (2009) 1.13
Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn (2005) 1.12
Runx2 phosphorylation induced by fibroblast growth factor-2/protein kinase C pathways. Proteomics (2006) 1.12
T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. J Neuroimmunol (2011) 1.12